Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 19, 2019 - Issue 10: Biosimilars
Submit an article Journal homepage
1,144
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases

Carla FeliceIBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information
,
Daniela PuglieseIBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, ItalyORCID Iconhttps://orcid.org/0000-0001-7930-5402View further author information
ORCID Icon &
Alessandro ArmuzziIBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence[email protected]
View further author information
Pages 967-969 | Received 18 Oct 2018, Accepted 02 Jan 2019, Published online: 11 Jan 2019

References

  • Lyman GH, Zon R, Harvey RD. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med. 2018 Aug 16;379(7):694–695. PubMed PMID: 30110587.
  • Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013 Oct;72(10):1605–1612. PubMed PMID: 23687259; PubMed Central PMCID: PMCPMC3786643.
  • Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013 Oct;72(10):1613–1620. PubMed PMID: 23687260; PubMed Central PMCID: PMCPMC3786641.
  • Komaki Y, Yamada A, Komaki F, et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 Apr;45(8):1043–1057. PubMed PMID: 28239873.
  • Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086):2304–2316. PubMed PMID: 28502609.
  • Armuzzi A, Fiorino G, Variola A, et al. The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy. Inflamm Bowel Dis. 2018 Aug 18. PubMed PMID: 30137352. DOI:10.1093/ibd/izy264
  • Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404–412. PubMed PMID: 29606564.
  • Numan S, Faccin F. Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies. Adv Ther. 2018 Sep;35(9):1295–1332. PubMed PMID: 30084060; PubMed Central PMCID: PMCPMC6133136.
  • Severs M, Oldenburg B, van Bodegraven AA, et al. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis. 2017 Mar 1;11(3):289–296. PubMed PMID: 27571772.
  • Armuzzi A, Avedano L, Greveson K, et al. Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease: education and communication strategies. J Crohns Colitis. 2018 Oct 4. PubMed PMID: 30285235. DOI:10.1093/ecco-jcc/jjy150
  • Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017 Jun 1;11(6):690–696. PubMed PMID: 28130330.
  • Peyrin-Biroulet L, Lonnfors S, Roblin X, et al. Patient perspectives on biosimilars: a survey by the European federation of Crohn’s and ulcerative colitis associations. J Crohns Colitis. 2017 Jan;11(1):128–133. PubMed PMID: 27481878.
  • Jacobs I, Singh E, Sewell KL, et al. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. 2016;10:937–948. PubMed PMID: 27307714; PubMed Central PMCID: PMCPMC4889091.
  • Pouillon L, Socha M, Demore B, et al. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018 Sep;14(9):739–749. PubMed PMID: 30118338.
  • Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018 May;74(5):655–661. PubMed PMID: 29368188; PubMed Central PMCID: PMCPMC5893662.
  • Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018 Jan;70(1):60–68. PubMed PMID: 29045077.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.